Ipriflavone inhibits bone resorption in intact and ovariectomized rats

Calcified Tissue International

Volumn 61, Issue SUPPL. 1, 1997, Pages

  Cecchini, M G ^a   Fleisch, H ^a   Muhlbauer R C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bone resorption; Ipriflavone; Ovariectomized rats

Indexed keywords

IPRIFLAVONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; ESTROGEN DEFICIENCY; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BONE REMODELING; BONE RESORPTION; DIET; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HUMANS; ISOFLAVONES; ISOTOPE LABELING; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; URINE; UTERUS;

EID: 0030806883     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900377     Document Type: Conference Paper

References (19)

1. Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passeri M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 51:82-91
2. Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, Cappelli N, Fioretti P (1993) Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 16:333-337
3. Valente M, Bufalino L, Castiglione GN, D'Angelo R, Mancuso A, Galoppi P, Zichella L (1994) Effect of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 54:377-380
4. Notoya K, Yoshida K, Taketomi S, Yamazaki I, Kumegawa M (1992) Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells. Calcif Tissue Int 51:S3-S6
5. Monta I, Sakagushi K, Kurachi T, Murota S (1992) Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int 51:S7-S10
6. Bonucci E, Ballanti P, Martelli A, Mereto E, Brambilla G, Bianco P, Bufalino L (1992) Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int 50:314-319
7. Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, Bufalino L, Serio M, Brandi ML (1991) Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 6:987-996
8. Notoya K, Yoshida K, Tsukuda R, Taketomi S (1994) Effect of ipriflavone on expression markers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture. J Bone Miner Res 9:395-400
9. Yamazaki I, Shino A, Tsukuda R (1986) Effect of ipriflavone on osteoporosis induced by ovariectomy in rats. J Bone Miner Metab 3:205-210
10. Mühlbauer RC, Fleisch H (1990) A method for continual monitoring of bone resorption in rats: evidence for a diurnal rhythm. Am J Physiol 259:R679-R689
11. Mühlbauer RC, Fleisch H (1995) The diurnal rhythm of bone resorption in the rat. Effect of feeding habits and pharmacological inhibitors. J Clin Invest 95:1933-1940
12. Cassidy A, Bingham S, Setchell KDR (1994) Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 60: 333-340
13. Petilli M, Fiorelli G, Benvenuti S, Frediani F, Gori F, Brandi ML (1995) Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int 56:160-165
14. Yamazaki I (1986) Effect of ipriflavone on the response of uterus and thyroid to estrogen. Life Sci 38:757-764
15. Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P (1992) Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 15:755-761
16. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU (1994) Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
17. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD (1995) Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136: 2435-2441
18. Black LJ, Jones CD, Falcone JF (1983) Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sci 32:1031-1036
19. Eppenberger U, Wosikowski K, Kung W (1991) Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol (suppl 2) 14:S5-S14